Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China

SUP will obtain regulatory approvals for selling Tiotropium DPI in China

Sanofi exercises license extension option to Nurix’s STAT6 program

his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

Auro Vaccines terminates license agreement with Hilleman Laboratories Singapore

This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials

Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology

Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement

IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)

MSD enters into license agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist

Merck closes license agreement for LM-299

Merck will record a pre-tax charge relating to the upfront payment of $588 million

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season